Stereological analysis of hippocampus in rat treated with chemotherapeutic agent oxaliplatin.

Stereological analysis of hippocampus in rat treated with chemotherapeutic agent oxaliplatin.

Related Articles

Stereological analysis of hippocampus in rat treated with chemotherapeutic agent oxaliplatin.

Folia Morphol (Warsz). 2020 Mar 11;:

Authors: Sadeghinezhad J, Amrein I

Abstract
BACKGROUND: Oxaliplatin (OX) has been widely used for treatment of colorectal and other cancers. Adverse effect of OX and other anticancer agents on cognition have been reported, but studies on the effects of chemotherapy on brain structure are scarce. This study describes the morphometrical features of the hippocampus structures in rat following OX treatment using design-based stereological methods.
MATERIALS AND METHODS: Ten male Wistar rats were randomized into two groups. The rats from OX group received 2.4 mg/kg OX in vehicle for five consecutive days every week for 2 weeks intraperitoneally (IP). Controls received vehicle only. Cavalieri ‘s method and the optical fractionator method were used for volume and neuron estimation, respectively.
RESULTS: Cavalieri ‘s method was used for to estimate volume and showed that the volume of the hippocampus was significantly decreased in OX group (31.84 ± 1.24 mm³) compared with the vehicle control group (36.95 ± 3.48 mm³). The optical fractionator method was used to estimate neuron number and showed that the number of neurons in dentate gyrus, cornu ammonis 1 and 3 in OX group (8.147 ± 2.84 × 10⁵, 4.257 ± 0.59 × 10⁵ and 2.133 ± 0.22 × 10⁵, respectively) did not differ from those of vehicle control group (7.36 ± 1.42 × 10⁵, 3.521 ± 0.54 × 10⁵ and 1.989 ± 0.46 × 10⁵, respectively).
CONCLUSIONS: These findings suggested that OX treatment induce loss of hippocampal volume without neuronal loss which might help to clarify the mechanism by which OX affects cognition and to improve preventive treatment strategies.

PMID: 32159839 [PubMed – as supplied by publisher]

Full Text Link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *